Insulin Syringes and Injection Technique

A “U-100” insulin syringe means the syringe is calibrated so that 100 units of fluid equals 1 mL. The barrel is graduated in unit ticks (not in mL), the needle is permanently attached, and the dead-space at the tip is minimized so the drawn volume matches the dose closely.

1. Calibration. U-100 (100 units = 1 mL). This is the only calibration relevant to peptide research; U-40 and U-500 exist but are insulin-specific.
2. Needle gauge. Typically 29–31 gauge. Higher number = thinner needle. Standard peptide-research gauge is 30 or 31.
3. Needle length. 5/16″ (8 mm) is the standard for subcutaneous injection. Longer lengths (1/2″, 12.7 mm) are reserved for intramuscular use, which is rarely the right route for peptides.
4. Why insulin syringes won. Most research peptides are dosed in microgram or low-milligram quantities, dissolved in a few mL of bacteriostatic water. The resulting injection volume is almost always under 50 units — well within insulin-syringe range — and the unit ticks give finer resolution than a standard 1 mL tuberculin syringe.
5. Short answer. Can you use insulin needles for peptides? — yes, and why they’re the standard tool.

The confusion comes from how insulin is dosed. Insulin is sold at a fixed concentration (U-100 = 100 units of insulin activity per mL), so for an insulin user, “units” on the syringe equals “units” of insulin. The two are the same number on purpose. Peptides don’t work that way: the concentration depends entirely on how much bacteriostatic water was used to reconstitute the vial, so the number of units drawn bears no fixed relationship to the milligrams or micrograms delivered until the reconstitution is specified.

Practical takeaway. Units describe how much liquid is in the syringe, not how much active peptide. Converting units to a peptide dose requires knowing the vial’s mg content and the reconstitution water volume — covered in the next section.

More water in the vial means lower concentration, which means more units (volume) needed to deliver the same mass dose. The formula:

Worked example. A 10 mg vial reconstituted three different ways, all targeting a 100 mcg dose:

Reconstitution determines the conversion. The same number of units delivers a different dose depending on how much water is in the vial. Recording the reconstitution volume on the vial label at the time of mixing, and checking it before each draw, is a commonly reported practice for avoiding a miscalculation. The Prof. Peptide dosage calculator handles this conversion automatically. For how the reconstitution volume sets the concentration, see how much bac water to add to peptides.

1. Dose volume drives barrel choice. The smallest barrel that can hold a given draw reads most precisely. A 5-unit dose on a 1 mL barrel sits between two tick marks; on a 0.3 mL barrel it lands cleanly on a labelled tick.
2. Why smaller is better for microdoses. Tick spacing scales with barrel length, not capacity, so a 0.3 mL barrel spreads 30 ticks across the same physical length as a 0.5 mL barrel spreads 50 ticks — the smaller barrel gives more space between each unit mark to read accurately.
3. Commonly reported practice. Vendor and community sources commonly report using 0.3 mL or 0.5 mL barrels for typical 2–10 unit peptide doses, stepping up to 1 mL only when the draw exceeds the smaller barrel’s capacity; Prof. Peptide has not independently verified this as a studied recommendation.
4. Needle is the same. Across these three sizes the needle itself (gauge and length) is typically identical — barrel capacity is the only meaningful variable.

Wegovy’s Instructions for Use (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, approved by FDA, May 2026) describes the following sequence for its prefilled syringe:

1. Hand washing. The instructions direct washing and drying hands before handling the syringe.
2. Site selection and cleaning. The instructions name the abdomen (at least 2 inches from the navel), the thighs, and the back of the upper arm (with assistance) as acceptable sites, and direct cleaning the site with an alcohol wipe and letting it dry before injecting.
3. Site rotation. The instructions direct avoiding the exact same spot used for the previous injection.
4. Needle exposure. The instructions direct removing the needle cap immediately before injecting and disposing of it in a sharps container, rather than recapping it — stated explicitly as a needlestick-injury precaution.
5. Skin fold. The instructions direct pinching and holding a fold of skin at the injection site between thumb and fingers, and maintaining that pinch through the injection.
6. Needle angle and insertion. The instructions specify a 45-degree angle, stated explicitly as being to reach the subcutaneous layer rather than muscle.
7. Delivering the dose. The instructions direct maintaining the 45-degree angle and pushing the plunger with constant, gentle pressure until it stops, at which point the dose is complete.
8. Withdrawal. The instructions direct pulling the syringe out at the same 45-degree angle, and, if blood appears at the site, pressing lightly with a cotton ball or gauze without rubbing — and again direct against recapping the needle.
9. Disposal. The instructions direct placing the used syringe in an FDA-cleared sharps disposal container immediately after use, and describe an acceptable household substitute (heavy-duty plastic, tight-fitting puncture-resistant lid, upright, leak-resistant, labeled) where one is not available, following local rules for its eventual disposal.

What this label does not cover. Wegovy’s Instructions for Use describes a prefilled, ready-to-inject syringe — it has no reconstitution step and does not address drawing a specific volume from a multi-dose vial by unit mark, since that is not how the approved product is dispensed. It also states only one needle angle (45 degrees) rather than a body-type-dependent choice; Prof. Peptide has not identified a labeled or published source describing a 90-degree option for a thicker skin fold, so none is presented here as sourced guidance.

Aspiration. Pulling back on the plunger after insertion to check for blood (“aspirating”) is not part of the Wegovy Instructions for Use sequence above, and is widely reported in nursing and diabetes-education literature as no longer recommended for subcutaneous injection generally — a practice Prof. Peptide has not sourced to a specific study for this page and reports here as commonly stated clinical guidance, not as an independently verified finding.

Reported factors in injection discomfort. Community and vendor sources commonly report that a cold solution, wet alcohol at the injection site, a reused needle, and repeated injection at the same site are each associated with more discomfort than their alternatives (room-temperature solution, fully dried alcohol, a fresh needle, and site rotation, respectively). Prof. Peptide has not identified a controlled study isolating these factors for a research peptide specifically, so this is reported as widely repeated observation, not as a sourced clinical finding.

1. Abdomen. Reported as the most-used site among peptide researchers, with substantial subQ fat and the fastest absorption of the common sites. Wegovy’s Instructions for Use specifies the abdomen “at least 2 inches from the belly button” as one of its named sites — the sourced figure for the exclusion radius around the navel, reused for this comparison.
2. Upper outer thigh. Named in Wegovy’s Instructions for Use as an acceptable site; reported as slower-absorbing than the abdomen. The outer/lateral portion is commonly reported as preferred over the inner thigh’s denser nerve and vessel network.
3. Back of upper arm. The triceps fold, named in Wegovy’s Instructions for Use as a site usable “only with help from someone else.” A thin build is reported to make this site harder to pinch than the abdomen or thigh.
4. Love handles / lower flank. The fatty area just above the iliac crest. Easy to pinch, well-tolerated, slowest absorption.

Site rotation. Alternate sides daily (left abdomen one day, right the next) and do not reuse the same spot for consecutive injections — repeated injection at one spot causes lipodystrophy (localized fat thickening or thinning) and slows absorption from that site over time. That much is what the prescribing information Prof. Peptide reads for its dosing guides instructs: rotate the site with each dose, within the same body region. A specific minimum distance and rest interval — commonly given as an inch or two, and a fortnight — is widely repeated, but Prof. Peptide has not found either figure in a manufacturer label or a published study, only on consumer apps and blogs, so neither is stated here.

Areas commonly reported as unsuitable. Scars, moles, tattoos, recently sunburned skin, areas with active rash, irritation or infection, and the area within 2 inches of the navel (per Wegovy’s Instructions for Use, above) are commonly reported as sites to avoid, along with any site that appears bruised, raised, or unusually red.

Absorption rate. Roughly abdomen > back of arm > thigh > flank. The difference matters most for fast-acting compounds (insulin, short-acting GH peptides); long-half-life peptides like the GLP-1 class are largely insensitive to site choice because steady-state plasma levels even out across the week.

1. Commonly reported response. Pressing a clean cotton pad or gauze on the site for 30-60 seconds is commonly reported to stop the bleeding; a few minutes of ice afterward is sometimes additionally reported to reduce bruising. Wegovy’s Instructions for Use similarly directs pressing lightly with a cotton ball or gauze if blood appears, without rubbing.
2. Typical bruising. A pea-sized bruise or yellow-purple mark appearing 1-2 days later is reported as a normal occurrence that resolves within about a week.
3. Site avoidance. A significant bleed or visible hematoma is commonly reported as a reason to avoid that specific area for roughly two weeks while the tissue heals.
4. Dose delivery. A nicked capillary is reported not to meaningfully affect peptide absorption; re-dosing to compensate is not indicated by any source Prof. Peptide identified.

When medical evaluation is warranted (rare). General injection-safety guidance describes bleeding that does not stop after 5 minutes of firm pressure, a rapidly expanding hematoma, severe unresolving pain, signs of infection (spreading redness, warmth, pus, fever) 24-48 hours later, or numbness or tingling extending away from the site as findings that warrant medical evaluation, distinct from routine bruising and minor bleeding.

1. Reconstitution & dose math. Prof. Peptide dosage calculator — enter vial mg, BAC water volume, and target dose; get units to draw on a U-100 syringe.
2. Peptide research fundamentals. Peptide research basics — vial handling, bacteriostatic water, storage, vendor selection, and quality verification.
3. Common peptide profiles. Most-referenced profiles for protocol context: Retatrutide, Tirzepatide, Semaglutide, BPC-157, Ipamorelin, CJC-1295.
4. Vendor and pricing references. Verified discount codes from vetted research peptide vendors.

Scope. Protocols, doses, and cycle lengths are peptide-specific and reported on the individual peptide profile and dosing-guide pages. This page covers technique — the mechanics of syringe use and subcutaneous injection — not what to take or how much.